Upregulation of MiR-142-3p Improves Drug Sensitivity of Acute Myelogenous Leukemia Through Reducing P-Glycoprotein and Repressing Autophagy by Targeting HMGB1

Overview

Journal Transl Oncol

Specialty Oncology

Date 2017 Apr 27

PMID 28445844

Citations 24

Authors

Yuan Zhang

Yufeng Liu

Xueju Xu

Affiliations

Soon will be listed here.

Abstract

miR-142-3p was reported to be downregulated in acute myelogenous leukemia (AML) and acted as a novel diagnostic marker. However, the regulatory effect of miR-142-3p on drug resistance of AML cells and its underlying mechanism have not been elucidated. Here, we found that miR-142-3p was significantly downregulated and high mobility group box 1 (HMGB1) was dramatically upregulated in AML samples and cells, as well as drug-resistant AML cells. P-gp level and autophagy were markedly enhanced in HL-60/ADR and HL-60/ATRA cells. miR-142-3p overexpression improved drug sensitivity of AML cells by inhibiting cell viability and promoting apoptosis, and inhibited P-gp level and autophagy in drug-resistant AML cells, whereas HMGB1 overexpression obviously reversed these effect. HMGB1 was demonstrated to be a target of miR-142-3p, and miR-142-3p negatively regulated HMGB1 expression. In conclusion, our study elucidated that upregulation of miR-142-3p improves drug sensitivity of AML through reducing P-glycoprotein and repressing autophagy by targeting HMGB1, contributing to better understanding the molecular mechanism of drug resistance in AML.

Citing Articles

Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies.

Anvari S, Nikbakht M, Vaezi M, Amini-Kafiabad S, Ahmadvand M Cancer Cell Int. 2024; 24(1):410.

PMID: 39702293 PMC: 11660508. DOI: 10.1186/s12935-024-03596-8.

Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges.

Tsilingiris D, Vallianou N, Spyrou N, Kounatidis D, Christodoulatos G, Karampela I Curr Obes Rep. 2023; 13(1):1-34.

PMID: 38159164 PMC: 10933194. DOI: 10.1007/s13679-023-00542-z.

Non-coding RNAs in leukemia drug resistance: new perspectives on molecular mechanisms and signaling pathways.

Rahmati A, Mafi A, Vakili O, Soleymani F, Alishahi Z, Yahyazadeh S Ann Hematol. 2023; 103(5):1455-1482.

PMID: 37526673 DOI: 10.1007/s00277-023-05383-3.

Mechanisms involved in the HMGB1 modulation of tumor multidrug resistance (Review).

Shao L, Zhu L, Wang M, Ning Y, Chen F, Gao X Int J Mol Med. 2023; 52(2).

PMID: 37387415 PMC: 10373125. DOI: 10.3892/ijmm.2023.5272.

The Promising Role of Non-Coding RNAs as Biomarkers and Therapeutic Targets for Leukemia.

Ghazimoradi M, Karimpour-Fard N, Babashah S Genes (Basel). 2023; 14(1).

PMID: 36672872 PMC: 9859176. DOI: 10.3390/genes14010131.

References

Nagano H, Tomimaru Y, Eguchi H, Hama N, Wada H, Kawamoto K . MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells. Int J Oncol. 2013; 43(4):1066-72. DOI: 10.3892/ijo.2013.2037. View

Grassilli S, Nika E, Lambertini E, Brugnoli F, Piva R, Capitani S . A network including PU.1, Vav1 and miR-142-3p sustains ATRA-induced differentiation of acute promyelocytic leukemia cells - a short report. Cell Oncol (Dordr). 2016; 39(5):483-489. DOI: 10.1007/s13402-016-0292-6. View

Zhi Y, Zhi F, Wang R, Xue L, Gu W, Wang B . [MicroRNA-10a expression in FAB different subtype of acute myeloid leukemia and its relationship with drug resistance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015; 23(1):29-33. DOI: 10.7534/j.issn.1009-2137.2015.01.006. View

Moretti L, Yang E, Kim K, Lu B . Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy. Drug Resist Updat. 2007; 10(4-5):135-43. DOI: 10.1016/j.drup.2007.05.001. View

Marin J, Briz O, Rodriguez-Macias G, Diez-Martin J, Macias R . Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia. Blood Rev. 2015; 30(1):55-64. DOI: 10.1016/j.blre.2015.08.001. View

Wang X, Zuo D, Yuan Y, Yang X, Hong Z, Zhang R . MicroRNA-183 promotes cell proliferation via regulating programmed cell death 6 in pediatric acute myeloid leukemia. J Cancer Res Clin Oncol. 2016; 143(1):169-180. DOI: 10.1007/s00432-016-2277-2. View

Marcucci G, Mrozek K, Radmacher M, Garzon R, Bloomfield C . The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 2010; 117(4):1121-9. PMC: 3056468. DOI: 10.1182/blood-2010-09-191312. View

Zhang H, Luo X, Feng D, Zhang X, Wu J, Zheng Y . Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer. 2011; 10:108. PMC: 3189170. DOI: 10.1186/1476-4598-10-108. View

Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y . HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia. 2010; 25(1):23-31. DOI: 10.1038/leu.2010.225. View

10.

Zhang R, Li Y, Wang Z, Chen L, Dong X, Nie X . Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis. Tumour Biol. 2015; 36(11):8585-92. DOI: 10.1007/s13277-015-3617-6. View

11.

Tang D, Kang R, Cheh C, Livesey K, Liang X, Schapiro N . HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 2010; 29(38):5299-310. PMC: 2945431. DOI: 10.1038/onc.2010.261. View

12.

Wang X, Gong J, Yu J, Wang F, Zhang X, Yin X . MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood. 2012; 119(21):4992-5004. DOI: 10.1182/blood-2011-10-385716. View

13.

Zheng T, Wang J, Chen X, Liu L . Role of microRNA in anticancer drug resistance. Int J Cancer. 2009; 126(1):2-10. DOI: 10.1002/ijc.24782. View

14.

Si X, Zhang X, Hao X, Li Y, Chen Z, Ding Y . Upregulation of miR-99a is associated with poor prognosis of acute myeloid leukemia and promotes myeloid leukemia cell expansion. Oncotarget. 2016; 7(47):78095-78109. PMC: 5363646. DOI: 10.18632/oncotarget.12947. View

15.

Pui C, Carroll W, Meshinchi S, Arceci R . Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011; 29(5):551-65. PMC: 3071256. DOI: 10.1200/JCO.2010.30.7405. View

16.

Zhan Z, Li Q, Wu P, Ye Y, Tseng H, Zhang L . Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1. Autophagy. 2011; 8(1):109-21. DOI: 10.4161/auto.8.1.18319. View

17.

Wang Y, Ouyang M, Wang Q, Jian Z . MicroRNA-142-3p inhibits hypoxia/reoxygenation‑induced apoptosis and fibrosis of cardiomyocytes by targeting high mobility group box 1. Int J Mol Med. 2016; 38(5):1377-1386. PMC: 5065300. DOI: 10.3892/ijmm.2016.2756. View

18.

Dou L, Li J, Zheng D, Li Y, Gao X, Xu C . MicroRNA-142-3p inhibits cell proliferation in human acute lymphoblastic leukemia by targeting the MLL-AF4 oncogene. Mol Biol Rep. 2013; 40(12):6811-9. DOI: 10.1007/s11033-013-2798-6. View

19.

Brown F, Cifani P, Drill E, He J, Still E, Zhong S . Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. Br J Haematol. 2016; 176(1):86-91. PMC: 5177472. DOI: 10.1111/bjh.14413. View

20.

Croce C . MicroRNA dysregulation in acute myeloid leukemia. J Clin Oncol. 2013; 31(17):2065-6. DOI: 10.1200/JCO.2013.48.8239. View